Source - RNS
RNS Number : 6727J
Shield Therapeutics PLC
13 September 2016


Shield Therapeutics plc

("Shield" or the "Company")


Grant of Share Awards


London, UK,  13th September 2016. Shield Therapeutics plc (LSE:STX), a specialty pharmaceutical company focused on secondary care, announces that, following approval at the AGM on 4th August 2016,  it has granted awards in the form of options over ordinary shares in the capital of the Company ("Award Shares") to the following executives under its Long Term Incentive Plan ("LTIP").


Carl Sterritt:                                       Director                               92,767

Richard Jones:                                   Director                               67,610

Paul Steckler                                      PDMR                                  58,176

Angela Hildreth                                 PDMR                                  34,591



In total awards have now been granted over 2,026,725 shares under the LTIP. The exercise price per Award Share is 1.5 pence and awards are exercisable between February 2019 and February 2026, subject to applicable performance conditions having been satisfied. The grant of awards is part of the Company's long-term incentive arrangements designed to directly align the interest of the shareholders and executives.


The Company's LTIP was adopted by the Board on 12th February 2016. The LTIP provides for awards of ordinary shares to be made to eligible employees. The arrangements are described more fully in the Admission Document, a copy of which is available on the Company's website (




For further information please contact:


Shield Therapeutics plc

+44 (0)191 511 8507

Carl Sterritt, Chief Executive Officer

Richard Jones, Chief Financial Officer




Nominated Adviser and Sole Broker

Liberum Capital Limited

Christopher Britton

Steve Pearce

Jamil Miah

+44 (0)20 3100 2222



Financial PR Advisor

Consilium Strategic Communications

+44 (0)203 709 5700

[email protected]

Mary-Jane Elliott

Matthew Neal

Lindsey Neville

Hendrik Thys



About Shield Therapeutics plc

Shield Therapeutics is a specialty pharmaceutical company focused on the commercialisation and development of late-stage, hospital-focused pharmaceuticals which address areas of unmet medical need. The Company has a marketed product, Feraccru®, for the treatment of iron deficiency anaemia (IDA) which has exclusive IP rights until 2034. In addition, the Company is developing PT20, a late-stage pharmaceutical for the treatment of systemic phosphate accumulation (hyperphosphatemia). Shield Therapeutics, headquartered in London, is listed on LSE's AIM under the ticker STX. For more information please visit


Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them



Details of the person discharging managerial responsibilities/person closely associated





Carl Sterritt:                       Director / PDMR

Richard Jones:                   Director / PDMR

Paul Steckler                      PDMR   

Angela Hildreth                 PDMR   



Reason for the notification





All PDMRs of Shield Therapeutics


Initial notification/ Amendment


Initial Notification


Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor





Shield Therapeutics plc






Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted



Description of the financial instrument, type of instrument




Identification code


Option over ordinary shares of 1.5p each in the capital of the Company







ISIN of Ordinary Shares: GB00BYV81293


Nature of the transaction


Grant of Options over ordinary shares in accordance with the Company's Long Term Incentive Plan


Price(s) and volume(s)


Exercise price: 1.5p



Carl Sterritt:                       92,767

Richard Jones:                   67,610

Paul Steckler                     58,176

Angela Hildreth                                34,591





Aggregated information


-      Aggregated volume


-    Price









Exercise price: 1.5p


Date of the transaction


12 September 2016


Place of the transaction


Outside a trading venue


Name of authorised official of issuer responsible for making notification.

Richard Jones

CFO and Company Secretary to Shield Therapeutics plc


This information is provided by RNS
The company news service from the London Stock Exchange